- Breast cancer
- Inflammatory breast cancer
- Invasive breast cancer
- Invasive ductal carcinoma
- Invasive lobular carcinoma
- Local tumor recurrence
- Male breast cancer
- Triple negative breast cancer
- Triple positive breast cancer
Igor Makhlin, MD
About me
- Assistant Professor of Clinical Medicine (Hematology-Oncology)
My education and training
- Geisinger Commonwealth School of MedicineMedical School
- Johns Hopkins HospitalResidency
- University of Pennsylvania Health SystemFellowship
Spoken languages
Reviews
Insurance accepted
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Qualifications and experience
- Internal Medicine, 2018
- Medical Oncology, 2021
- American College of Physicians, National
- American Medical Association, National
- American Society of Clinical Oncology, National
- Gilead Sciences, National
- Pennsylvania Medical Society, Local
- Breast cancer care
All conditions and treatments
Research
Publications
Lawrence-Paul MR, Pan TC, Pant DK, Shih NNC, Chen Y, Belka GK, Makhlin I, Curtis C, DeMichele AM, Chodosh LA. Mutability Dependence of Breast Cancer Metastasis and Latency to Recurrence , Cancer Discov: 2026
Kathleen Doheny Tumor Genomic Testing: Too Little, Too Late , Medscape: 2026
Angus Chen Many cancer patients don’t get genomic tests to guide treatment, study finds , STAT News - https://www.statnews.com/2026/04/07/genomic-tests-needed-for-targeted-cancer-treatments/: 2026
Makhlin I. The Role of Molecular Profiling in Achieving Guideline-Concordant Care-From Sequencing to Survival , JAMA Netw Open, 9: 2026,e265596
Igor Makhlin Dr Makhlin on Data to Support the Use of FES-PET/CT in Breast Cancer Management , Onc Live, 1(1): 2026
Makhlin, Igor Reality Check: Palbociclib in Metastatic Breast Cancer Leveraging Real-World Evidence to Support Effectiveness , JAMA Network Open, Accepted for Publication: 2026
DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, Dwyer S, Pan TC, Nivar I, Chen Y, Wileyto P, Berry LR, Deluca S, Savage J, Makhlin I, Pant DK, Martin H, Egunsola A, Mears N, Goodspeed BL, Chislock EM, Graves J, Wang J, Shih N, Belka GK, Berry D, Nayak A, Feldman M, Chodosh LA. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial , Nat Med: 2025
Jacob B. Reibel, Christopher A. D’Avella, Igor Makhlin2 , Mengru Wang, Maneet Kaur , Yunzhi Qian, Rebecca L. Maniago, Ivy P. Altomare, Lawrence N. Shulman Guideline concordant osimertinib and durvalumab in two US non-small cell lung cancer cohorts. , ASCO Quality Care Symposium: 2025
Igor Makhlin Dissecting Biologic Risk Using Genomic Assays - Implications for Extended Endocrine Therapy and Beyond , JAMA Network Open - In Press: 2024
Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A. Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights , JCO Oncol Pract: 2024